1
|
Blow T, Hyde PN, Falcone JN, Neinstein A, Vasan N, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integr Cancer Ther 2021; 20:15347354211032283. [PMID: 34259084 PMCID: PMC8283040 DOI: 10.1177/15347354211032283] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Alpelisib is a α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor approved for
treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative (HER2–), PIK3CA-mutated, advanced breast
cancer (ABC). Hyperglycemia is a common, on-target adverse effect that impairs treatment
efficacy and increases the rate of treatment delays, dose reductions, and discontinuation.
Currently, there are no clear guidelines on how to manage hyperglycemia due to alpelisib
when metformin is not effective. In this case series, we review 3 subjects with ABC that
developed hyperglycemia during alpelisib-fulvestrant therapy and were successfully managed
with dietary and pharmacologic interventions. These cases provide anecdotal evidence to
support the use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and very low
carbohydrate diets to minimize hyperglycemia during alpelisib therapy.
Collapse
Affiliation(s)
- Tahj Blow
- Weill Cornell Medicine, New York, NY, USA
| | - Parker N Hyde
- University of North Georgia, Dahlonega, GA, USA.,The Ohio State University, Columbus, OH, USA
| | | | - Aaron Neinstein
- University of California, San Francisco, San Francisco, CA, USA
| | - Neil Vasan
- Weill Cornell Medicine, New York, NY, USA.,Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | - Sagar Sardesai
- The Ohio State University, Columbus, OH, USA.,The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Maryam B Lustberg
- The Ohio State University, Columbus, OH, USA.,The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - James H Flory
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | |
Collapse
|